Arcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) Report
August 31, 2023 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Company shows advancement toward improving patient care, access and affordability, social capital, drug safety, sustainability, and ethical business practices WESTLAKE VILLAGE, Calif., Aug. 31, 2023...
Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%
August 29, 2023 08:00 ET
|
Arcutis Biotherapeutics, Inc.
The Cream That Can is a direct-to-consumer ad highlighting that clear skin is possible with ZORYVEZORYVE is a once-daily, steroid-free cream for individuals with plaque psoriasis 12 years and above...
Arcutis Appoints Interim Chief Financial Officer (CFO)
August 18, 2023 16:30 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful...
Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia
August 10, 2023 08:16 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis to receive $30 million upfront payment and is eligible to receive potential development and commercial milestone payments, as well as double digit tiered royalties WESTLAKE VILLAGE,...
Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update
August 08, 2023 16:02 ET
|
Arcutis Biotherapeutics, Inc.
Achieved total revenues of $5.2 million in the second quarter of 2023. Net product revenues for ZORYVE® (roflumilast) cream 0.3% were $4.8 million, a 72% increase compared to the first quarter of...
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2023 16:00 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful...
Arcutis to Report Second Quarter Financial Results
July 24, 2023 16:00 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful...
Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark
July 17, 2023 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Coverage at CVS Caremark, the largest pharmacy benefit manager (PBM) in the United States was effective July 5All three of the largest pharmacy benefit managers in the United States have now included...
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 05, 2023 16:00 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful...
Arcutis to Present at Upcoming Investor Conference
June 06, 2023 16:00 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in...